Literature DB >> 11018648

Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine.

C J Pachuk1, R B Ciccarelli, M Samuel, M E Bayer, R D Troutman, D V Zurawski, J I Schauer, T J Higgins, D B Weiner, D M Sosnoski, V R Zurawski, C Satishchandran.   

Abstract

Bupivacaine, a local anesthetic and cationic amphiphile, forms stable liposomal-like structures upon direct mixing with plasmid DNA in aqueous solutions. These structures are on the order of 50-70 nm as determined by scanning electron microscopy, and are homogeneous populations as analyzed by density gradient centrifugation. The DNA within these structures is protected from nuclease degradation and UV-induced damage in vitro. Bupivacaine:DNA complexes have a negative zeta potential (surface charge), homogeneous nature, and an ability to rapidly assemble in aqueous solutions. Bupivacaine:DNA complexes, as well as similar complexes of DNA with other local anesthetics, have the potential to be a novel class of DNA delivery agents for gene therapy and DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018648     DOI: 10.1016/s0005-2736(00)00242-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  DNA vaccines: developing new strategies to enhance immune responses.

Authors:  Shaheed A Abdulhaqq; David B Weiner
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Cell targeting in anti-cancer gene therapy.

Authors:  Mohd Azmi Mohd Lila; John Shia Kwong Siew; Hayati Zakaria; Suria Mohd Saad; Lim Shen Ni; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2004-01

Review 3.  Possible Reversal of PTSD-Related DNA Methylation by Sympathetic Blockade.

Authors:  Eugene G Lipov; Kenneth Candido; Elspeth C Ritchie
Journal:  J Mol Neurosci       Date:  2017-03-31       Impact factor: 3.444

4.  Anti-caries DNA vaccine-induced secretory immunoglobulin A antibodies inhibit formation of Streptococcus mutans biofilms in vitro.

Authors:  Li Huang; Qing-an Xu; Chang Liu; Ming-wen Fan; Yu-hong Li
Journal:  Acta Pharmacol Sin       Date:  2012-12-31       Impact factor: 6.150

5.  Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.

Authors:  Amara Luckay; Maninder K Sidhu; Rune Kjeken; Shakuntala Megati; Siew-Yen Chong; Vidia Roopchand; Dorys Garcia-Hand; Rashed Abdullah; Ralph Braun; David C Montefiori; Margherita Rosati; Barbara K Felber; George N Pavlakis; Iacob Mathiesen; Zimra R Israel; John H Eldridge; Michael A Egan
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

6.  Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.

Authors:  Shakuntala Megati; Dorys Garcia-Hand; Sarah Cappello; Vidia Roopchand; Amjed Masood; Rong Xu; Amara Luckay; Siew-Yen Chong; Margherita Rosati; Solomon Sackitey; David B Weiner; Barbara K Felber; George N Pavlakis; Zimra R Israel; Larry R Smith; John H Eldridge; Maninder K Sidhu; Michael A Egan
Journal:  Vaccine       Date:  2008-04-24       Impact factor: 3.641

7.  Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.

Authors:  Margherita Rosati; Antonio Valentin; Rashmi Jalah; Vainav Patel; Agneta von Gegerfelt; Cristina Bergamaschi; Candido Alicea; Deborah Weiss; Jim Treece; Ranajit Pal; Phillip D Markham; Ernesto T A Marques; J Thomas August; Amir Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2008-04-21       Impact factor: 3.641

8.  Enhancing specific-antibody production to the ragB vaccine with GITRL that expand Tfh, IFN-γ(+) T cells and attenuates Porphyromonas gingivalis infection in mice.

Authors:  Dong Zheng; Qiang Sun; Zhaoliang Su; Fanzhi Kong; Xiaoju Shi; Jia Tong; Pei Shen; Tianqing Peng; Shengjun Wang; Huaxi Xu
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

9.  Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.

Authors:  Rong Xu; Shakuntala Megati; Vidia Roopchand; Amara Luckay; Amjed Masood; Dorys Garcia-Hand; Margherita Rosati; David B Weiner; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; John H Eldridge; Michael A Egan
Journal:  Vaccine       Date:  2008-07-25       Impact factor: 4.169

10.  A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Authors:  Juliet Mpendo; Gaudensia Mutua; Julien Nyombayire; Rosine Ingabire; Annet Nanvubya; Omu Anzala; Etienne Karita; Peter Hayes; Jakub Kopycinski; Len Dally; Drew Hannaman; Michael A Egan; John H Eldridge; Kristen Syvertsen; Jennifer Lehrman; Beth Rasmussen; Jill Gilmour; Josephine H Cox; Patricia E Fast; Claudia Schmidt
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.